4.4 Article Proceedings Paper

Terazosin, doxazosin, and prazosin: Current clinical experience

期刊

UROLOGY
卷 58, 期 6A, 页码 49-54

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0090-4295(01)01302-4

关键词

-

向作者/读者索取更多资源

Lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction are common in aging men. Nearly 25% of men > 40 years of age have LUTS. Medical therapy with a-blockade is the most common method of medical therapy for benign prostatic obstruction. Multiple methods of minimally invasive surgical therapies have been introduced in the last decade. These methods include balloon dilatation, temporary and permanent urethral stents, various laser techniques, microwave thermotherapy, transurethral needle ablation, electrovaporization, and high-intensity focused ultrasound. alpha -Receptor blockers to reduce the sympathetic tone of the prostate are considered as first-line therapy to relieve the symptoms of benign prostatic hyperplasia. Selective alpha (1)-receptor blockers relax prostatic smooth muscle, relieve bladder outlet obstruction, and enhance urine flow with fewer side effects. In addition, it was determined that treating patients with alpha (1)-blockers increases prostatic apoptosis. Pharmacokinetic activity, mode of action, clinical efficacy, and side effects of the selective alpha (1)-receptor blockers terazosin, doxazosin, and prazosin are reviewed. (C) 2001, Elsevier Science Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据